Press Enter to search · Esc to close
A massive new target-trial emulation hints that semaglutide and tirzepatide may do more than shrink waistlines — they may quietly cut the odds of obesity-driven cancers. Here's what the data actually say.
New meta-analyses suggest the metabolic-drug story is moving past the scale — toward measurable inflammation reduction and stacked cardiorenal protection. Here's what that actually changes for a 40-year-old.
A network meta-analysis finally ranks the incretin heavyweights head-to-head, while a novel once-weekly peptide files its first big numbers. Here's what the data actually shows.
A landmark phase 3 trial puts the dual-receptor agonist on the map for adolescents with type 2 diabetes — and new mechanistic work suggests its effects reach all the way down to the mitochondrion.
Three new clinical analyses cut through the semaglutide and tirzepatide hype — quantifying real-world weight loss at one year, the muscle question lifters keep asking, and what happens when patients head into the OR.
A dual GIP/GLP-1 agonist already changing diabetes and obesity care is now posting credible early signals against the fatty-liver disease that often travels with them.
A wave of 2025 analyses is dissecting the real mechanisms behind the headline weight loss — and the picture is messier, smarter, and more interesting than the marketing.
New research is beginning to explain why GLP-1 drugs work brilliantly for some and modestly for others — and what comes after the first generation of blockbusters.
Semaglutide, exendin-4, and tirzepatide are pushing GLP-1 receptor agonists into hepatology and cardiology — while a fresh case report reminds us the safety ledger is still open.
A new meta-analysis pooling seven direct comparisons gives us the cleanest apples-to-apples read yet on how the two big incretin drugs stack up for weight loss.